Weekly intelligence on China biotech deals, CDE filings, and BIOSECURE compliance.
16 issues published · Every Thursday since December 2025
Showing 5 briefings tagged “Bispecific”
Early 2026 deal data confirms the acceleration: average deal sizes are tracking 76% larger than 2025, with average values reaching $1.3 billion. We analyze the structural drivers, track the BIOSECURE BCC list countdown (9 months to go), and preview the spring conference season.
The FDA has accepted Summit Therapeutics' BLA for ivonescimab with a PDUFA target action date of November 14, 2026. We analyze what this means for the bispecific competitive landscape and track the latest BIOSECURE SEC disclosure wave.
Takeda paid $1.2 billion upfront to Innovent Biologics for rights to IBI363 and IBI343 — the largest upfront payment ever for Chinese-developed antibody assets. We analyze the deal structure, the competitive implications, and what this signals for 2026 BD strategy.
Summit Therapeutics submitted a BLA to the FDA for Akeso's ivonescimab (PD-1/VEGF bispecific) in EGFR-mutant NSCLC. If approved, it would be the first China-originated bispecific antibody to reach the US market — and a validation of the entire China-to-West licensing model.
Chinese drug makers signed 157 out-licensing deals worth $136 billion in 2025 — nearly triple 2024. We break down the full-year numbers, the five mega-deals that defined the market, and what the data tells us about 2026.
Get new briefings delivered
Every Thursday. Free. Unsubscribe anytime.